CD37 and cancer: CD37 expressing cancers have been targeted with several antibody-based therapies, including Fc engineered antibodies (BI836826), drug or radio immunoconjugates (maytansinoid DM1 IMGN529; monomethyl auristatin E, AGS67E, and (177 Lu) Betalutin), DuoHexaBody-CD37, and single-chain variable fragments (ScFv) (Otlertuzumab/TRU-016), either alone or in combination with rituximab, chemotherapy, or other agents [22,27,28,29,30,31,32].